Biotechnology

LEADS BIOLABS-B

Vilithibio's Partner Advances Clinical Development of LBL-047

GF Securities Analyst Maintains Buy Rating on Nanjing Wellicybo-B

Vilithibio-B's PD-L1/4-1BB Bispecific Antibody OPATIMUSUMAB Phase II Clinical Trial First Patient Enrolled

VilitionBio-B to Present Two Preclinical Pipeline Research Results at AACR Annual Meeting in 2026

LEADS BIOLABS-B released FY2025 annual earnings on March 27 (BJT), actual revenue HKD 193.73 M (forecast HKD 246.48 M), actual EPS HKD -1.3268 (forecast HKD -1.1992)

LEADS BIOLABS-B released FY2024 Q3 earnings on March 27 (BJT), actual revenue HKD 0, actual EPS HKD -0.4389

LEADS BIOLABS-B released FY2024 Q4 earnings on March 27 (BJT), actual revenue HKD 0, actual EPS HKD -0.4212

LEADS BIOLABS-B released FY2025 Q4 earnings on March 27, 2026 (BJT), actual revenue HKD 98.56 M, actual EPS HKD -0.1297

LEADS BIOLABS-B released FY2024 9 months earnings on March 27 (BJT), actual revenue HKD 0, actual EPS HKD -1.7585

LEADS BIOLABS-B released FY2025 Q3 earnings on March 27, 2026 (BJT), with actual revenue of HKD 96.88 M and EPS of HKD -0.1283

LEADS BIOLABS-B released FY2025 9 Months earnings on March 27, 2026 (BJT), actual revenue HKD 96.88 M, actual EPS HKD -1.2806

LEADS BIOLABS-B to Release FY2025 Earnings on March 27, 2026 (BJT), Forecast Revenue HKD 247.6 M, EPS HKD -1.2047

Multinational Pharma Companies Increase Interest in Chinese Innovative Drugs, Industry Development Environment Improved

Vilithibio-B Successfully Administers First Patient in Ib/II Clinical Trial for Triple-Negative Breast Cancer

VilitionBio-B's LBL-034 Granted FDA Fast Track Designation

Vilithibo's Vilixin Obtains Orphan Drug Designation from EU

Vyligend-B's Vilixin (LBL-024) Granted FDA Fast Track Designation

VilithiBio-B Begins Phase Ib/II Clinical Trial for PD-L1/4-1BB Bispecific Antibody in Platinum-Resistant Ovarian Cancer

Vilimiabo Announces Clinical Trial Results of GPRC5D/CD3 Bispecific Antibody LBL-034 at ASH Annual Meeting

Vilithibio-B's Self-Developed Candidate Drug LBL-047 Approved for Clinical Trials by NMPA

FAMEGLOW

TJCD

ZHONGSHENJIANYE

NEW GONOW RV

ZXZN QI-HOUSE

51WORLD

EASYHOLD GROUP

CH CITY INFRA

INTELLIMARK W27

GREEN BROAD

09887

516930

516500

159837

159849

Nanjing Leads Biolabs Co., Ltd. has received approval from the Hong Kong Stock Exchange for the listing of 44,391,598 converted H shares under its H Share Full Circulation program. This conversion involves 23 shareholders and aims to enhance liquidity and marketability of the company's equity. The move is expected to broaden the investor base and strengthen its position in the biotech sector. The latest analyst rating for the stock (HK:9887) is a Buy with a price target of HK$100.50.

Tip Ranks

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

HKEX

HKEX-R

Hong Kong Exchanges and Clearing (HKEX)

Nanjing Leads Biolabs Wins HKEX Approval for H-Share Full Circulation

02661

00326

02565

01626

02255

09936

02575

00290

02632

QINGSONG HEALTH(02661) fell 24.2%, with a trading turnover 244.8 Million HKD, and a year-to-date fell 57.2%. CHINA STAR ENT(00326) fell 20.14%, with a trading turnover 119.0 Million HKD, and a year-to-date rose 123.4%. PEGBIO CO-B(02565) fell 19.15%, with a trading turnover 53.6 Million HKD, and a year-to-date fell 71.7%.

Top Gainers&Losers

QINGSONG HEALTH

CHINA STAR ENT

PEGBIO CO-B

JIA YAO HLDGS

HAICHANG HLDG

XIMEI RESOURCES

XUANZHUBIO-B

GOFINTECH QUANT

NEW VISION CO

Top 10 HK Stock Losers (5.13)

GF Securities analyst maintained a Buy rating on Nanjing Leads Biolabs Co., Ltd. Class H yesterday and set a price target of HK$110.96.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nanjing Leads Biolabs Co., Ltd. Class H with a HK$112.65 average price target.

GF SECURITIES

GF SEC

GF Securities Sticks to Its Buy Rating for Nanjing Leads Biolabs Co., Ltd. Class H (9887)

Nanjing Leads Biolabs Co., Ltd. has scheduled its 2026 AGM for May 15, 2026, to review its 2025 performance and governance plans. Shareholders will vote on the board’s reports, profit distribution, and appointing Dr. Wu Fenglan as a non-executive director. The board seeks a mandate to issue up to 20% of share capital for financing flexibility. The latest analyst rating for the stock (HK:9887) is a Buy with a target price of HK$100.50. Nanjing Leads Biolabs specializes in innovative biological drugs and is listed in Hong Kong with a market cap of HK$16.28B.

Nanjing Leads Biolabs Calls 2026 AGM and Seeks Fresh Share Issuance Mandate

Nanjing Leads Biolabs Co., Ltd. has initiated a Phase II clinical trial for its bispecific antibody Opamtistomig (LBL-024) targeting gastric cancer. The trial, led by Professor Shen Lin at Beijing Cancer Hospital, aims to evaluate the drug's efficacy and safety in patients with advanced gastric adenocarcinoma. Opamtistomig has shown promise in treating various tumors and has received regulatory designations in multiple regions. Analysts rate the stock (HK:9887) as a Buy with a price target of HK$100.50, highlighting its potential in the competitive immuno-oncology market.

Nanjing Leads Biolabs Starts Phase II Trial of Opamtistomig in Gastric Cancer

02655

02517

06656

01384

02595

02656

06660

03986

02788

GUOXIA TECH(02655) fell 24.04%, with a trading turnover 653.6 Million HKD, and a year-to-date rose 9.2%. GUOQUAN(02517) fell 11.17%, with a trading turnover 338.8 Million HKD, and a year-to-date fell 13.4%. SIGENERGY(06656) fell 9.02%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 85.1%.

GUOXIA TECH

GUOQUAN

SIGENERGY

DEEPEXI TECH

GENFLEET-B

160 HEALTH

AIM VACCINE

GIGADEVICE

CHUANGXIN IND

Top 10 HK Stock Losers (4.17)

02513

02442

02526

03636

09880

06600

09966

06636

09995

KNOWLEDGE ATLAS(02513) rose 31.94%, with a trading turnover 5.0 Billion HKD, and a year-to-date rose 687.4%. EASY SMART GP(02442) rose 31.13%, with a trading turnover 32.0 Million HKD, and a year-to-date rose 91.4%. DIAGENS-B(02526) rose 24.34%, with a trading turnover 161.2 Million HKD, and a year-to-date rose 148.7%.

KNOWLEDGE ATLAS

EASY SMART GP

DIAGENS-B

JINXUN RESOURCE

UBTECH ROBOTICS

ONEROBOTICS

ALPHAMAB-B

EXTREME VISION

REMEGEN

Top 10 HK Stock Gainers (4.1)

HKXCY

BABA

GELYY

The Hang Seng Index closed at 25,276 points, up 488 points or 2.0%. The Hang Seng TECH Index reported 4,723 points, up 73 points or 1.6%. The China Enterprises Index rose 129 points or 1.5%, closing at 8,503 points. Hong Kong Exchanges and Clearing increased by 3.3% to HKD 401.4, Alibaba rose by 2.9% to HKD 122.4, and Tencent increased by 2.6% to HKD 496.4. Several stocks, including China National Pharmaceutical Group and BeiGene, performed outstandingly, while Geely reached a new high, closing at HKD 21.7, up 3.7%

AASTOCKS

Alibaba

Geely Auto

ICBC

GEELY AUTOMOBILE HOLDINGS LIMITED SPON ADS EACH REP 20 ORD

Tencent

Hang Seng Index

Hang Seng TECH Index

WH GROUP

BABA-W

TENCENT

FL2 CSOP HSI

KraneShares 2x Long BABA Daily ETF

FI CSOP HSI

BABA 2x Long Daily ETF - GraniteShares

FI2 CSOP HSI

CSOP HS TECH

"Half-Day Express" Hang Seng Index rises 488 points; Hang Seng TECH Index rises 73 points, HKEX rises over 3%, Geely, WH GROUP, ICBC, Bank of China, LEADS BIOLABS-B hit new highs

02609

00100

Hong Kong stock market overview in the past hour Market sentiment seems to be gradually warming up amid recent fluctuations, especially with strong performances in the healthcare and technology sectors. Capital flows are clearly favoring small-cap stocks and emerging industries, with short-term enthusiasm rising, driving overall gains. BAYZED HEALTH's strong surge has attracted market attention, and other related stocks have also become active, creating a positive linkage effect. Overall, stocks with significant gains are mostly concentrated in the pharmaceutical and technology sectors, indicating investors' preference for these areas. The stock with the largest movement in the past hour, BAYZED HEALTH, surged 20.20%, becoming the market focus. The stock quickly rose in the early trading phase, attracting a large influx of capital, with short-term sentiment running high, driving subsequent buying. The market's optimistic expectations for its future development seem to provide strong support. Strong stocks 1. EXTREME VISION: up 15.63%, recent market attention on its technological innovations has increased, with noticeable capital inflow. 2. MINIMAX-W: up 15.33%, active short-term capital, with market sentiment high, driving rapid price increases. 3. FLOWING CLOUD: up 15.29%, performing well driven by technology stocks, attracting considerable short-term capital. 4. LEPU BIO-B: up 15.17%, strong performance in the pharmaceutical sector supports its stock price's continuous rise. 5. CIFI HOLD GP: up 15.15%, with optimistic expectations for its future performance, capital continues to flow in

HK Stock Alerts

BAYZED HEALTH

MINIMAX-W

FLOWING CLOUD

LEPU BIO

CIFI HOLD GP

LINGBAO GOLD

COSCO SHIP ENGY

TONGGUAN GOLD

Hong Kong Stock Movement Update: The medical technology sector rebounds strongly, BAYZED HEALTH surges 20% to lead the gains!

159615

159102

513120

Nanjing Leads Biolabs Co., Ltd. announced the resignation of non-executive director Dr. Ni Jia effective March 27, 2026, with no disagreements noted. The company plans to appoint Dr. Wu Fenglan as a new non-executive director, pending shareholder approval, to enhance governance and strategic positioning. Dr. Wu brings extensive experience in R&D, fundraising, and healthcare investments, which is expected to support the company's growth in innovative drugs. The current analyst rating for Nanjing Leads Biolabs stock (HK:9887) is a Buy with a price target of HK$80.27.

China Southern Hang Seng Biotech ETF(QDII)

Huaan Hang Seng Biotech ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Nanjing Leads Biolabs Reshapes Board With Non-Executive Director Change

LEADS BIOLABS-B(09887.HK)